Correlation of Serum Galectin-3 Level with Renal Volume and Function in Adult Polycystic Kidney Disease

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2019 Apr 24

PMID 31012038

Citations 6

Authors

Sultan Ozkurt

Ibrahim Dogan

Oguzhan Ozcan

Nurdan Fidan

Ilter Bozaci

Behice Yilmaz

Muzaffer Bilgin

Affiliations

Soon will be listed here.

Abstract

Purpose: The decrease in kidney functions in autosomal dominant polycystic kidney disease (ADPKD) is strongly correlated with the severity and growth of kidney cysts. Total kidney volume (TKV) was shown to be an early marker of the severity of the disease and a predictor of reduction in kidney functions. New treatment approaches for ADPKD have led to a need for easily applicable strong biomarkers predicting progression of the disease. The profibrotic mediator of galectin-3 (Gal-3) is linked to development of renal fibrosis.

Methods: The study included 74 patients with ADPKD diagnosis and 40 healthy controls. The TKV of patients was calculated using the manual tracing method on MR images. The serum Gal-3 levels of patient and healthy control groups were measured with the ELISA method. The correlations between serum Gal-3 value with TKV and kidney function were assessed in patients.

Results: As the stage of chronic kidney disease (CKD) increased, serum Gal-3 and TKV values increased (p < 0.001, p = 0.049, respectively). Correlation analysis found a negative relationship between serum Gal-3 levels and eGFR (r: - 0.515, p < 0.001); however, there was no relationship between serum Gal-3 and TKV (r = 0.112, p = 0.344). Linear regression analysis showed the major parameter affecting Gal-3 was eGFR (p = 0.016).

Conclusions: In our study, we showed that renal impairment is an important determinant of Gal-3, and there is no correlation of Gal-3 and TKV in ADPKD. As a result, there is an urgent clinical need for new biomarkers to identify individuals with the chance of treatment in the early stage among ADPKD patients.

Citing Articles

Total kidney volume in autosomal dominant polycystic kidney disease: intraobserver and interobserver agreement of two methods with MRI.

Gundogdu E, Cihan C, Yazici C Turk J Med Sci. 2024; 54(3):537-544.

PMID: 39049998 PMC: 11265870. DOI: 10.55730/1300-0144.5820.

Galectin-3: action and clinical utility in chronic kidney disease.

Syn G, Lee Y, Lim Z, Chan G Int Urol Nephrol. 2024; 56(11):3535-3543.

PMID: 38861106 DOI: 10.1007/s11255-024-04107-4.

On Whether Ca-125 Is the Answer for Diagnosing Overhydration, Particularly in End-Stage Kidney Disease Patients-A Systematic Review.

Nikitiuk B, Rydzewska-Rosolowska A, Kakareko K, Glowinska I, Hryszko T Int J Mol Sci. 2024; 25(4).

PMID: 38396869 PMC: 10889175. DOI: 10.3390/ijms25042192.

Measurement of Plasma Galectin-3 Concentrations in Patients with Catheter Infections: A Post Hoc Retrospective Cohort Study.

Iftimie S, Hernandez-Aguilera A, Lopez-Azcona A, Castane H, Rodriguez-Tomas E, Baiges-Gaya G Diagnostics (Basel). 2022; 12(10).

PMID: 36292107 PMC: 9599992. DOI: 10.3390/diagnostics12102418.

A Systematic Review of Reported Outcomes in ADPKD Studies.

Jdiaa S, Husainat N, Mansour R, Kalot M, McGreal K, Chebib F Kidney Int Rep. 2022; 7(9):1964-1979.

PMID: 36090492 PMC: 9459055. DOI: 10.1016/j.ekir.2022.06.012.

References

Bao Q, Hughes R . Galectin-3 and polarized growth within collagen gels of wild-type and ricin-resistant MDCK renal epithelial cells. Glycobiology. 1999; 9(5):489-95. DOI: 10.1093/glycob/9.5.489. View

Mann D . Inflammatory mediators in heart failure: homogeneity through heterogeneity. Lancet. 1999; 353(9167):1812-3. DOI: 10.1016/S0140-6736(99)90069-7. View

Nishiyama J, Kobayashi S, Ishida A, Nakabayashi I, Tajima O, Miura S . Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol. 2000; 157(3):815-23. PMC: 1885699. DOI: 10.1016/S0002-9440(10)64595-6. View

Hikita C, Vijayakumar S, Takito J, Erdjument-Bromage H, Tempst P, Al-Awqati Q . Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin 3. J Cell Biol. 2000; 151(6):1235-46. PMC: 2190595. DOI: 10.1083/jcb.151.6.1235. View

Bullock S, Johnson T, Bao Q, Hughes R, Winyard P, Woolf A . Galectin-3 modulates ureteric bud branching in organ culture of the developing mouse kidney. J Am Soc Nephrol. 2001; 12(3):515-523. DOI: 10.1681/ASN.V123515. View

Guay-Woodford L, Desmond R . Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics. 2003; 111(5 Pt 1):1072-80. DOI: 10.1542/peds.111.5.1072. View

Chapman A, Guay-Woodford L, Grantham J, Torres V, Bae K, Baumgarten D . Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003; 64(3):1035-45. DOI: 10.1046/j.1523-1755.2003.00185.x. View

Sharma U, Pokharel S, van Brakel T, van Berlo J, Cleutjens J, Schroen B . Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110(19):3121-8. DOI: 10.1161/01.CIR.0000147181.65298.4D. View

Grantham J, Torres V, Chapman A, Guay-Woodford L, Bae K, King Jr B . Volume progression in polycystic kidney disease. N Engl J Med. 2006; 354(20):2122-30. DOI: 10.1056/NEJMoa054341. View

10.

Grantham J, Chapman A, Torres V . Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2007; 1(1):148-57. DOI: 10.2215/CJN.00330705. View

11.

Bertocchi A, Campanhole G, Wang P, Goncalves G, Damiao M, Cenedeze M . A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl Int. 2008; 21(10):999-1007. DOI: 10.1111/j.1432-2277.2008.00705.x. View

12.

Dhirapong A, Lleo A, Leung P, Gershwin M, Liu F . The immunological potential of galectin-1 and -3. Autoimmun Rev. 2008; 8(5):360-3. DOI: 10.1016/j.autrev.2008.11.009. View

13.

Kang E, Moon K, Lee E, Lee Y, Lee E, Ahn C . Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus. 2008; 18(1):22-8. DOI: 10.1177/0961203308094361. View

14.

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

15.

Henderson N, Sethi T . The regulation of inflammation by galectin-3. Immunol Rev. 2009; 230(1):160-71. DOI: 10.1111/j.1600-065X.2009.00794.x. View

16.

de Boer R, Voors A, Muntendam P, van Gilst W, Van Veldhuisen D . Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009; 11(9):811-7. DOI: 10.1093/eurjhf/hfp097. View

17.

Lin Y, Lin L, Wu Y, Chien K, Lee C, Hsu R . The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta. 2009; 409(1-2):96-9. DOI: 10.1016/j.cca.2009.09.001. View

18.

Dancer J, Truong L, Zhai Q, Shen S . Expression of Galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med. 2010; 134(1):90-4. DOI: 10.5858/2008-0392-OAR1.1. View

19.

Lok D, van der Meer P, Bruggink-Andre de la Porte P, Lipsic E, Wijngaarden J, Hillege H . Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010; 99(5):323-8. PMC: 2858799. DOI: 10.1007/s00392-010-0125-y. View

20.

Vansthertem D, Cludts S, Nonclercq D, Gossiaux A, Saussez S, Legrand A . Immunohistochemical localization of galectins-1 and -3 and monitoring of tissue galectin-binding sites during tubular regeneration after renal ischemia reperfusion in the rat. Histol Histopathol. 2010; 25(11):1417-29. DOI: 10.14670/HH-25.1417. View